Screener
Sutro Biopharma STRO Income Statement
| Q3 '26 | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | ||
|---|---|---|---|---|---|---|
| $9.1M-6.1% | $9.84M-84.6% | $14.52M-16.5% | $11.65M-21.4% | $9.69M+13.8% | ||
| $23.5M-41.0% | $31.7M-17.3% | $36.55M-29.2% | $36.64M-48.4% | $39.85M-35.8% | ||
| $7.54M-13.8% | $7.83M-24.3% | $7.58M-42.9% | $8.66M-4.1% | $8.74M-39.0% | ||
| $31.05M-46.6% | $39.73M-40.8% | $44.18M-48.6% | $49.7M-37.9% | $58.15M-23.9% | ||
| -$21.96M+54.7% | -$29.89M-794% | -$29.66M+56.7% | -$38.05M+41.7% | -$48.46M+28.7% | ||
| -241.3%+259pp | -303.8%-299pp | -204.2%+190pp | -326.7%+114pp | -499.9%+297pp | ||
| -$31.49M+44.6% | -$38.53M-235% | -$38.5M+49.3% | -$46.84M+33.2% | -$56.86M-16.5% | ||
| $0— | $1K+106% | -$15K-314% | -$82K-103% | $0— | ||
| -$31.49M+44.6% | -$38.53M-235% | -$38.48M+49.3% | -$46.76M+35.4% | -$56.86M-16.5% | ||
| -346.1%+240pp | -391.6%-374pp | -265%+172pp | -401.5%+87.7pp | -586.6%-14.0pp | ||
| -$1.90-184% | -$2.33-72.6% | -$2.94+67.6% | -$20.78+24.0% | -$0.67-13.6% | ||
| -$20.71M+55.5% | -$28.63M-1,881% | -$28.38M+57.4% | -$36.43M+42.5% | -$46.56M+29.6% | ||
| -227.7%+253pp | -290.9%-289pp | -195.4%+187pp | -312.7%+115pp | -480.3%+296pp | ||
| -$21.96M+54.7% | -$29.89M-794% | -$29.66M+56.7% | -$38.05M+41.7% | -$48.46M+28.7% |
FAQ
- What is Sutro Biopharma's revenue?
- Sutro Biopharma (STRO) generated $45.1M in revenue over the trailing twelve months, down 57.3% year over year.
- Is Sutro Biopharma profitable?
- Sutro Biopharma is not currently profitable: it reported a net loss of $155.3M over the trailing twelve months, a -344.2% net margin.
- What is Sutro Biopharma's earnings per share?
- Sutro Biopharma's diluted EPS over the trailing twelve months is $-27.95.
- Where does Sutro Biopharma's income statement data come from?
- Every line is extracted from Sutro Biopharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
